Effects of sodium-glucose co-transporter 2 inhibitors on ultrafiltration in patients with peritoneal dialysis: a protocol for a randomized, double-blind, placebo-controlled, crossover trial (EMPOWERED)

Doi, Yohei; Shinzawa, Maki; Arisato, Tetsuya; Oka, Hideaki; Matsumoto, Ayumi; Kitamura, Harumi; Nakazono, Yumi; Nishiya, Yoichi; Ueda, Yoshiyasu; Kamimura, Taro; Hayashi, Terumasa; Yoshihara, Fumiki; Isaka, Yoshitaka

doi:https://doi.org/10.1007/s10157-024-02467-w

Effects of sodium-glucose co-transporter 2 inhibitors on ultrafiltration in patients with peritoneal dialysis: a protocol for a randomized, double-blind, placebo-controlled, crossover trial (EMPOWERED)

Doi, Yohei; Shinzawa, Maki; Arisato, Tetsuya et al.

Clinical and Experimental Nephrology, 2024, 28, 629-635

アクセス数:1,308件（2025-09-12 08:48 集計）

固定URL: https://hdl.handle.net/11094/95017

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
ClinExpNephrol_s10157-024-02467-w	pdf	なし	677 KB	286	2024.04.12

Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Effects of sodium-glucose co-transporter 2 inhibitors on ultrafiltration in patients with peritoneal dialysis: a protocol for a randomized, double-blind, placebo-controlled, crossover trial (EMPOWERED)
著者	NRID 1000030846382 1000030846382 ORCID 0000-0002-5165-291X 0000-0002-5165-291X researchmap permalink DOI-YOHEI DOI-YOHEI 著者名 Doi, Yohei
	NRID 1000030704788 1000030704788 researchmap permalink 7000009447 7000009447 Scopus Author ID 47661817400 47661817400 著者名 Shinzawa, Maki
	著者名 Arisato, Tetsuya
	著者名 Oka, Hideaki
	NRID 1000040794053 1000040794053 著者名 Matsumoto, Ayumi
	NRID 1000060570356 1000060570356 researchmap permalink kitamura3857 kitamura3857 Scopus Author ID 24334934300 24334934300 著者名 Kitamura, Harumi
	著者名 Nakazono, Yumi
	著者名 Nishiya, Yoichi
	著者名 Ueda, Yoshiyasu
	著者名 Kamimura, Taro
	著者名 Hayashi, Terumasa
	NRID 1000070393220 1000070393220 著者名 Yoshihara, Fumiki
	NRID 1000000379166 1000000379166 researchmap permalink isaka-handai3857 isaka-handai3857 Scopus Author ID 16207611100 16207611100 ORCID 0000-0002-0820-7167 0000-0002-0820-7167 著者名 Isaka, Yoshitaka
キーワード等	Peritoneal dialysis
	SGLT2 inhibitor
	Ultrafiltration
	Volume overload
内容	The version of record of this article, first published in Clinical and Experimental Nephrology, is available online at Publisher’s website: https://doi.org/10.1007/s10157-024-02467-w.
抄録	Background: Volume overload is common and associated with high mortality in patients on peritoneal dialysis (PD). Traditional strategies including diuretics, water/salt restriction, and icodextrin-based solutions cannot always fully correct this condition, necessitating novel alternative strategies. Recent studies confirmed the expression of sodium–glucose cotransporter 2 (SGLT2) in the human peritoneum. Experimental data suggest that SGLT2 inhibitors decrease glucose absorption from the PD solution, thereby increasing the ultrafiltration volume. This trial aims to assess whether SGLT2 inhibitors increase the ultrafiltration volume in patients on PD. Methods: The EMPOWERED trial (trial registration: jRCTs051230081) is a multicenter, randomized, double-blind, placebo-controlled, crossover trial. Patients with clinically diagnosed chronic heart failure are eligible regardless of the presence of diabetes if they use at least 3 L/day glucose-based PD solutions. Participants will be randomly assigned (1:1) to receive empagliflozin 10 mg once daily and then placebo or vice versa. Each treatment period will last 8 weeks with a 4-week washout period. This study will recruit at least 36 randomized participants. The primary endpoint is the change in the daily ultrafiltration volume from baseline to week 8 in each intervention period. The key secondary endpoints include changes in the biomarkers of drained PD solutions, renal residual function, and anemia-related parameters. Conclusions: This trial aims to assess the benefit of SGLT2 inhibitors in fluid management with a novel mechanism of action in patients on PD. It will also provide insights into the effects of SGLT2 inhibitors on solute transport across the peritoneal membrane and residual renal function.
出版者	Springer
収録物名	Clinical and Experimental Nephrology
巻(号)	28
ページ	629-635
刊行年月	2024-02-25
言語	英語
ハンドルURL	https://hdl.handle.net/11094/95017
PISSN	13421751
eISSN	14377799
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1007/s10157-024-02467-w
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Clinical and Experimental Nephrology. 2024, 28, p. 629-635
DC.title	Effects of sodium-glucose co-transporter 2 inhibitors on ultrafiltration in patients with peritoneal dialysis: a protocol for a randomized, double-blind, placebo-controlled, crossover trial (EMPOWERED)
DC.creator	Doi, Yohei
	Shinzawa, Maki
	Arisato, Tetsuya
	Oka, Hideaki
	Matsumoto, Ayumi
	Kitamura, Harumi
	Nakazono, Yumi
	Nishiya, Yoichi
	Ueda, Yoshiyasu
	Kamimura, Taro
	Hayashi, Terumasa
	Yoshihara, Fumiki
	Isaka, Yoshitaka
DC.publisher	Springer
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-02-25
DC.identifier	https://doi.org/10.1007/s10157-024-02467-w
DC.subject	Peritoneal dialysis
	SGLT2 inhibitor
	Ultrafiltration
	Volume overload
DC.description	The version of record of this article, first published in Clinical and Experimental Nephrology, is available online at Publisher’s website: https://doi.org/10.1007/s10157-024-02467-w.
DCTERMS.abstract	Background: Volume overload is common and associated with high mortality in patients on peritoneal dialysis (PD). Traditional strategies including diuretics, water/salt restriction, and icodextrin-based solutions cannot always fully correct this condition, necessitating novel alternative strategies. Recent studies confirmed the expression of sodium–glucose cotransporter 2 (SGLT2) in the human peritoneum. Experimental data suggest that SGLT2 inhibitors decrease glucose absorption from the PD solution, thereby increasing the ultrafiltration volume. This trial aims to assess whether SGLT2 inhibitors increase the ultrafiltration volume in patients on PD. Methods: The EMPOWERED trial (trial registration: jRCTs051230081) is a multicenter, randomized, double-blind, placebo-controlled, crossover trial. Patients with clinically diagnosed chronic heart failure are eligible regardless of the presence of diabetes if they use at least 3 L/day glucose-based PD solutions. Participants will be randomly assigned (1:1) to receive empagliflozin 10 mg once daily and then placebo or vice versa. Each treatment period will last 8 weeks with a 4-week washout period. This study will recruit at least 36 randomized participants. The primary endpoint is the change in the daily ultrafiltration volume from baseline to week 8 in each intervention period. The key secondary endpoints include changes in the biomarkers of drained PD solutions, renal residual function, and anemia-related parameters. Conclusions: This trial aims to assess the benefit of SGLT2 inhibitors in fluid management with a novel mechanism of action in patients on PD. It will also provide insights into the effects of SGLT2 inhibitors on solute transport across the peritoneal membrane and residual renal function.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	95017
citation_title	Effects of sodium-glucose co-transporter 2 inhibitors on ultrafiltration in patients with peritoneal dialysis: a protocol for a randomized, double-blind, placebo-controlled, crossover trial (EMPOWERED)
citation_author	Doi, Yohei
	Shinzawa, Maki
	Arisato, Tetsuya
	Oka, Hideaki
	Matsumoto, Ayumi
	Kitamura, Harumi
	Nakazono, Yumi
	Nishiya, Yoichi
	Ueda, Yoshiyasu
	Kamimura, Taro
	Hayashi, Terumasa
	Yoshihara, Fumiki
	Isaka, Yoshitaka
citation_publisher	Springer
citation_language	英語
citation_date	2024-02-25
citation_journal_title	Clinical and Experimental Nephrology
citation_volume	28
citation_firstpage	629
citation_lastpage	635
citation_doi	https://doi.org/10.1007/s10157-024-02467-w
citation_public_url	https://hdl.handle.net/11094/95017

Effects of sodium-glucose co-transporter 2 inhibitors on ultrafiltration in patients with peritoneal dialysis: a protocol for a randomized, double-blind, placebo-controlled, crossover trial (EMPOWERED)

閲覧可能ファイル

論文情報

論文詳細を表示